Each film-coated tablet contains Baricitinib INN 2 mg.
Baricitinib is a selective & reversible inhibitor of Janus kinase JAK1 and JAK2. In isolated enzyme assays, Baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 & JAK3 with IC50 values of 5.9, 5.7, 53 and > 400 nM respectively. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines & growth factors involved in haematopoiesis, inflammation & immune function. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 & JAK2 enzymatic activity, thereby reducing the phosphorylation & activation of STATs.
Route of Administration: Oral. ¹ tablet once daily. Or as directed by the physician.
With medicine: The recommended dose of Baricitinib in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (e.g., probenecid) is 1 mg once daily. With food & others: No interaction with food & others.
Overdose:
Diarrhoea.
There are no adequate and well-controlled studies in pregnant women. It is not known whether Baricitinib is excreted in human milk.
Safety and efficacy in children have not been established.
Baricitinib should be discontinued in case of severe active infection. Not indicated in Tuberculosis patient. May increase the risk of thrombosis. Gastro-intestinal perforation: Not indicated for patients who are in risk of gastro-intestinal perforation. Patient should not take any live vaccine during treatment with Baricitinib.
Store below 30°C temperature & in dry place, protected from light. Keep out of the reach of children.